Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers28. September 2017|In Portfolio News|By eazee-designstudioImmatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program. PrevNext
